MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

AbbVie Inc

Open

BrancheGesundheitswesen

185.23 3.08

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

178.98

Max

186.19

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.6B

-23M

Verkäufe

642M

15B

KGV

Branchendurchschnitt

71.496

57.333

EPS

2.16

Dividendenrendite

3.86

Gewinnspanne

-0.152

Angestellte

55,000

EBITDA

-4.4B

535M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+17.54% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.86%

2.63%

Nächstes Ergebnis

25. Apr. 2025

Nächste Dividendenausschüttung

15. Mai 2025

Nächstes Ex-Dividendendatum

14. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-29B

306B

Vorheriger Eröffnungskurs

182.15

Vorheriger Schlusskurs

185.23

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

AbbVie Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Apr. 2025, 18:18 UTC

Wichtige Markttreiber

Pharma Shares Reverse Losses After Tariff Pause

9. Apr. 2025, 09:39 UTC

Wichtige Markttreiber

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

27. Feb. 2025, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12. Feb. 2025, 13:41 UTC

Wichtige Markttreiber

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31. Jan. 2025, 13:28 UTC

Ergebnisse

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14. März 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3. März 2025, 15:04 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6. Feb. 2025, 13:25 UTC

Top News
Ergebnisse

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6. Feb. 2025, 12:00 UTC

Ergebnisse

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5. Feb. 2025, 12:00 UTC

Top News

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31. Jan. 2025, 15:50 UTC

Top News
Ergebnisse

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31. Jan. 2025, 13:51 UTC

Ergebnisse

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31. Jan. 2025, 13:47 UTC

Top News
Ergebnisse

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31. Jan. 2025, 13:24 UTC

Market Talk
Ergebnisse

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31. Jan. 2025, 12:46 UTC

Ergebnisse

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31. Jan. 2025, 12:39 UTC

Ergebnisse

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31. Jan. 2025, 12:38 UTC

Ergebnisse

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31. Jan. 2025, 12:38 UTC

Ergebnisse

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31. Jan. 2025, 12:37 UTC

Ergebnisse

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31. Jan. 2025, 12:37 UTC

Ergebnisse

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Loss $22M >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Adj EPS $2.16 >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31. Jan. 2025, 12:36 UTC

Ergebnisse

AbbVie 4Q Loss/Shr 2c >ABBV

Peer-Vergleich

Kursveränderung

AbbVie Inc Prognose

Kursziel

By TipRanks

17.54% Vorteil

12-Monats-Prognose

Durchschnitt 212 USD  17.54%

Hoch 241 USD

Tief 190 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AbbVie Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

13

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

174.2 / 180.5Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.